We intend to focus on businesses in Asia (excluding China, Hong Kong and Macau) with enterprise values between $200 million and $600 million. (Incorporated in the Cayman Islands) (Note: TenX Keane Acquisition priced its SPAC IPO on Oct. 13, 2022, in line with the terms in its prospectus: 6.0 million units at $10.00 each to […]

We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. (Incorporated in Delaware) Our product candidates are derived from donor cells (allogeneic) rather than a patient’s own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient’s treatment […]

(Note: This is NOT an IPO. This is a NASDAQ uplisting from the Tel Aviv Stock Exchange. IPOScoop has NO CALL on uplistings. This public offering/uplisting is a unit offering with proposed symbol “SVRE” for the stock and proposed symbol “SVREW” for the warrant. Each unit consists of one American Depositary Share (ADS) and one […]

(Note: This is an IPO unit offering. IPOScoop has NO CALL on unit IPOs. Locafy Limited is offering 1.82 million units – up to $10 million in estimated IPO proceeds – at an IPO price expected to be between $4.50 and $6.50 per unit, according to its F-1/A filing dated March 7, 2022. The assumed […]

We are a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). That target has been found on an expanding number of pathogens. While the ultimate decision on the safety and efficacy of our therapeutics […]

We intend to focus on the entertainment and real estate sectors, including experiential entertainment. (Incorporated in the Cayman Islands) Jonathan Goldstein, the founder and CEO of Cain International, is our chairman, CEO and CFO. (Note: Cain Acquisition filed to go public in March 2021 and withdrew its SPAC IPO registration on March 7, 2022.)

We believe that we are a world leading entrepreneur Edtech and education group. Our mission is to disrupt the current education model with a student-centered, lifelong learning curriculum that prepares students with the leadership, entrepreneurial and life skills to succeed in today’s market. To help achieve our mission, we are growing from a Pre-IPO Group […]

We are a pre-clinical biopharmaceutical company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. Our research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which we believe plays a key role in the pathology of these inflammatory eye diseases of high unmet medical […]

Our mission is to broaden access to the multicultural education system of Canada through advanced management and technological innovation and to facilitate the achievement of a student’s full potential regardless of social or immigration status. We are a licensed provider of private online and in person educational programs and services in Canada, serving both Canadian […]

We are a clinical-stage biopharmaceutical company developing treatments for rare, chronic and serious infectious diseases with high unmet needs. Our initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Epetraborole has broad spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. […]